Čeština | Dansk | Deutsch | English | Español | Français | Italiano | Nederlands | Norsk | Polski | Português | Pусский | Suomi | Svenska | US
Euro Huntington's disease network [logo]
EHDN2016 DISEASE NETWORK REGISTRY PROJECTS LOGIN
 
 
  
Experimental Rx -
--->Uutiset
[-]Projekti
--->Rahoittaja
--->[-]Johtokunta
--->Arnesen
--->Blumenstein
--->Burgunder
--->Craufurd
--->Humbert
--->Jones
--->Kremer
--->Reilmann
--->Roos
--->Rosser
--->Weydt
--->Capper-Loup
--->Feihle
--->Levey
--->McLean
--->Julkiset asiakirjat
--->[+]Writing Committee Strategic ...
--->[-]Neuvoa antava lautakunta
--->Becanovic
--->Busse
--->Frontali
--->Giorgini
--->Holmans
--->Mariotti
--->Norremolle
--->Reetz
--->Rickards
--->Saft
--->van Duijn
--->Valenza
--->Verellen
--->Julkiset asiakirjat
--->Keskuskoordinaatio
--->Kielikoordinaatio
--->Fellowship Programme
--->[-]Perustuslaki 2008
--->Article 1
--->Article 2
--->Article 3
--->Article 4
--->Article 5
--->Article 6
--->Article 7
--->Article 8
--->Article 9
--->Article 10
--->Article 11
--->Article 12
--->Documents
--->[+]Äänestys
--->[-]Jäsenet
--->Jäsenyyden hakeminen
[-]Tutkimuspaikat
--->[+]Itävalta
--->[+]Belgia
--->[+]Tsekin tasavalta
--->[+]Tanska
--->[+]Suomi
--->[+]Ranska
--->[+]Saksa
--->[+]Ireland
--->[+]Italia
--->[+]Alankomaat
--->[+]Norja
--->[+]Puola
--->[+]Portugali
--->[+]Russia
--->[+]Espanja
--->[+]Ruotsi
--->[+]Sveitsi
--->[-]Iso-Britannia
--->Coordination
--->HD Associations
--->Links
--->[+]UKHDN
--->Standard of Care
--->Aberdeen
--->[+]Ayr
--->Belfast
--->Birmingham
--->[+]Blandford Forum
--->Bristol
--->Cambridge
--->Cardiff
--->Dundee
--->Edinburgh
--->Exeter
--->Fife
--->Forth Valley
--->Glasgow
--->Gloucester
--->Hull
--->Inverness
--->Launceston
--->Leeds
--->Leicester
--->Liverpool
--->London - Guy's Hospital
--->London - Hammersmith
--->London - NHNN
--->London - Royal Hospital
--->London - St. George´s
--->Manchester
--->Newcastle-Upon-Tyne
--->[+]Northampton
--->Nottingham
--->Oxford
--->[+]Plymouth
--->Poole
--->Preston
--->Reading
--->[+]Sheffield
--->Southampton
--->Stoke-on-Trent
--->Swindon
--->Wrexham
--->[+]Outside Europe
[-]Työryhmät
--->[-]Advanced HD
--->Dates
--->[+]Meetings
--->[-]Behavioural Phenotype
--->Dates
--->[+]Meetings
--->[+]Psycho appr. & interv. Sub...
--->[+]Biological Modifiers
--->[+]Biomarkers
--->[+]Brainbanking
--->[-]Cognitive Phenotype
--->[+]Päivämäärät
--->[+]Meetings
--->[+]Environmental Modifiers
--->[-]Functional Ability
--->Dates
--->[+]Meetings
--->[+]Genetic Testing
--->[-]Genetic Modifiers
--->[+]Päivämäärät
--->[+]Meetings
--->[+]Health Economics
--->[-]Imaging
--->[-]Päivämäärät
--->[+]Meetings
--->[-]Juveniili Huntingtonin tauti
--->Päivämäärät
--->[+]Motor Phenotype
--->[-]Neuroprotective Rx
--->[+]Päivämäärät
--->[+]Meetings
--->[-]Physiotherapy
--->Dates
--->[+]Meetings
--->[-]Quality of Life
--->[+]Päivämäärät
--->[+]Meetings
--->[-]Standard of Care
--->[+]Päivämäärät
--->[+]Meetings
--->[+]Dieticians
--->[+]SALT
--->[+]Dental care
--->[+]Occupational
--->[+]Surgical Therapy
--->[-]Symptomatic Rx
--->[+]Päivämäärät
--->[+]Meetings
--->[+]Young Adults
[-]Tapahtumat
--->[-]EHDN 2016
--->Announcement
--->Introduction
--->Registration
--->Programme Fri
--->Programme Sat
--->Programme Sun
--->Additional Meetings
--->Floor plan
--->[+]Overduin Registration
--->CME points
--->Sponsoring
--->Travel Information
--->Hotel booking
--->Social activities
--->Reimbursement
--->[+]Abstract Submission
--->Contacts
--->Documents
--->Feedback
--->EHDN 2014
--->Announcement
--->Introduction
--->Registration
--->Programme Fri
--->Programme Sat
--->Programme Sun
--->Additional Meetings
--->CME points
--->Sponsoring
--->Travel Information
--->Hotel Booking
--->Reimbursement
--->Social Activities
--->[+]Abstract Submission
--->Contacts
--->Feedback
--->[-]EHDN 2012
--->Introduction
--->Announcement
--->Programme Fri
--->Programme Sat
--->Programme Sun
--->Additional Meetings
--->Important Dates
--->Registration
--->[+]Travel & Accommodation
--->[+]EHA Registration
--->EHA Programme
--->Reception Dinner
--->About Stockholm
--->[+]Abstract Submission
--->Reimbursement
--->[-]Documents
--->Handouts
--->Presentations
--->[-]Posters
--->Pathogenic mechanisms
--->Animal models
--->Choreatic disorders - no...
--->Genetic modifiers
--->Wet Biomarkers
--->Imaging
--->Clin characteristics
--->Clin char-motor
--->Clin char-cognitive
--->Clin char - behaviour
--->Clin char-other
--->Clinical studies
--->Genetic testing
--->Clinical care
--->Experimental Rx
--->Clinical Rx
--->Non-scientific
--->Contacts
--->Feedback & Evaluation
--->[-]EHDN 2010
--->Introduction
--->Programme I
--->Programme II
--->Additional Meetings
--->Registration
--->EHA Programme
--->[+]EHA Registration
--->Plenary Dinner
--->Social Programme
--->Important Dates
--->[+]Abstract Submission
--->Reimbursement
--->Hotel Booking
--->[+]Travel and Location
--->[+]About Prague
--->Documents
--->Committees
--->Contact
--->Feedback & Evaluation
--->[-]EHDN 2008
--->Programme
--->Additional Meetings
--->EHA Programme
--->Social Programme
--->Kids Programme
--->Important Dates
--->Voting
--->Reimbursement
--->[+]Registration
--->[+]Abstract Submission
--->Evaluation & Feedback
--->[+]Travel and Location
--->[+]About Lisbon
--->[+]Documents
--->Committees
--->Contact
--->[+]EHDN 2007
--->[-]EHDN 2006
--->Introduction
--->Final Programme
--->Plenary Dinner
--->Meeting Venue
--->[+]About Blankenberge
--->[-]EHDN 2005
--->Final Programme
--->Plenary Dinner
--->Registration
--->Working Groups
--->Meeting Venue
--->Manchester
--->Evaluation & Feedback
--->[+]EHDN 2004
[-]Yhteydenpito
--->Yhteydenottolomake
--->Chatti-huoneet
--->Sähköpostilistat - julkinen
--->Newsletter
--->Työtarjoukset
päivämääräkuvauskokokirjoittaja asiakirja 
04.08.26In vivo efficacy of (CUG)n oligonucleotides to treat HD32 kBanonymousapplication/mswordp02-in-vivo-efficacy-oligonucleotides 
04.08.26Antisense oligonucleotide mediated transcript reduction and modulation – the European approach to develop a therapy for Huntington Disease32 kBanonymousapplication/mswordp01-antisense-oligonucleotide-transcript 
04.08.26Reducing toxic n-terminal Huntingtin fragments in HD using exon skipping32 kBanonymousapplication/mswordp03-exon-skipping 
04.08.26A Huntingtin peptide inhibits polyQ-hHtt associated defects32 kBanonymousapplication/mswordp04-polyq-hhtt-associated-defects 
04.08.26Astrocytes affect neuroprotection: Glatiramer acetate in Huntington`s Disease therapy32 kBanonymousapplication/mswordp07-glatiramer-acetate 
04.08.26Olesoxime improves specific features of the HD pathology32 kBanonymousapplication/mswordp06-olesoxime 
04.08.26Analysis of Nrf2-downstream targets after fumarate treatment in dorsal root ganglia – an anti-inflammatory therapy in neurodegenerative disease?!32 kBanonymousapplication/mswordp08-analysis-of-nrf2 

Kansio sisältää 7 asiakirjaa.
about us | privacy statement | disclaimer | terms of use